Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter

Clearance of Inflammatory Cytokines in Patients With Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMIC®2 Filter

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03231748

Acronym

ClicAKI

Enrollment

Registered

2017-07-27

Start date

2017-07-01

Completion date

2018-07-01

Last updated

2019-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Renal Failure

Brief summary

This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy. The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.

Detailed description

In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis * clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary

Exclusion criteria

* lack of consent * pre-existing dialysis dependent renal failure * life expectancy \<24 hours * patients with haemoglobin \<7g/dL (unless transfused for clinical reasons) * need for extracorporeal membrane oxygenation (ECMO)

Design outcomes

Primary

Measure	Time frame	Description
Removal of inflammatory mediators	48 hours	Clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor

Secondary

Measure	Time frame	Description
Adsorption of inflammatory mediators	48 hours	Adsorption of IL-1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor

Countries

United Kingdom

Outcome results